RT Journal Article
SR Electronic
T1 Inhaled corticosteroids (ICS) attenuates epithelial mesenchymal transition (EMT) in COPD: A key to understanding long term benefits?
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1439
VO 40
IS Suppl 56
A1 Sukhwinder Singh Sohal
A1 Amir Soltani
A1 David Reid
A1 Chris Ward
A1 Steven Weston
A1 Hans Konrad Muller
A1 Richard Wood-Baker
A1 Eugene Haydn Walters
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P1439.abstract
AB Introduction: We recently published that EMT is an active process in COPD airways. Our knowledge about the effects of ICS on this process in COPD is very limited.Objective: To assess the effects of ICS on EMT in endobronchial biopsies (ebb) from COPD patients.Methods: A double-blinded, randomized, placebo-controlled study assessed the effects of inhaled fluticasone propionate (FP; 500µg twice daily) on EMT in 34 COPD patients. Ebb were assessed for EMT related reticular basement membrane (Rbm) fragmentation and immunostained for the EMT signatures S100A4 (a fibroblast epitope), matrix-metalloproteinase-9 (MMP-9) and epithelial activation marker, epidermal growth factor receptor (EGFR).Results:View this table:Comparison at baseline and after treatment (FP, n=23 and placebo, n=11)Conclusions: This is the first study to report that ICS have potent anti-EMT effects in COPD. This may be a mechanistic link between ICS treatment and long term reduction in smoking-related lung cancer seen in COPD.